Previous 10 | Next 10 |
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP TM ) therapy platform, today reported its financial results for the quarter en...
RenovoRx ( NASDAQ: RNXT ) appoints James Ahlers as CFO, effective July 15, 2022, and the addition of Ronald B. Kocak as VP and Controller. Mr. Ahlers replaces Christopher J. Lehman, who joined in connection with its IPO and is leaving to pursue a n...
Expands Finance Team with Addition of Ronald B. Kocak, CPA as Vice President and Controller RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Financial Officer (CF...
Series Spotlights the RenovoRx Journey, its Leadership and Innovative Treatment Platform Targeting Difficult-to-Treat Cancers RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted ca...
“Facing Today’s Challenges in Pancreatic Cancer Treatment: Understanding RenovoRx’s Trans-Arterial Micro-Perfusion Therapy Platform” RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, t...
Dr. Ramtin Agah to Present, “ Localized Intra-arterial Drug Delivery for Treatment of Solid Tumors” RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will participate in the Gateway ...
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced management’s participation in the H.C. Wainwright Global Investment Conference on May 23-26, 2022 in Miam...
RenovoRx press release (NASDAQ:RNXT): Q1 net loss of $3M. Cash and cash equivalents as of March 31, 2022, were $13.1 million. For further details see: RenovoRx reports Q1 results
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the quarter ended March 31, 2022. “As we report our Q1 2022 results, we ...
Gainers: Clarus Therapeutics Holdings (CRXT) +87%. Winc (WBEV) +27%. AlloVir (ALVR) +26%. NexImmune (NEXI) +24%. Charah Solutions (CHRA) +22%. Target Hospitality (TH) +20%. Phio Pharmaceuticals (PHIO) +20%. Healthcare Services Group (HCSG) +19%. CEL-SCI (CVM) +18%. Biophytis (BPTS) +17%. Lose...
News, Short Squeeze, Breakout and More Instantly...
LOS ALTOS, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today annou...
LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...